Literature DB >> 12884867

Type-1 polarized nature of mouse liver CD8alpha- and CD8alpha+ dendritic cells: tissue-dependent differences offset CD8alpha-related dendritic cell heterogeneity.

Peta J O'Connell1, Young-Ik Son, Adam Giermasz, Zhiliang Wang, Alison J Logar, Angus W Thomson, Pawel Kalinski.   

Abstract

Interleukin-12 p70 (IL-12p70) is a major dendritic cell (DC)-produced cytokine known to support type-1 T helper (Th1) cells and inflammatory-type immunity. While the ability of DC to produce bioactive IL-12p70 depends on both the DC subtype and the microenvironmental conditions of DC development, the relative contribution of each of these factors remains unclear. Here, we report that in contrast to spleen CD8alpha+ and CD8alpha- DC that show strong differences in their respective IL-12p70-producing capacities, CD8alpha+ and CD8alpha- DC isolated from the liver, a non-lymphoid organ, both efficiently produce IL-12p70 in amounts comparable to spleen CD8alpha+ DC. The IL-12p70-producing capacity CD8alpha+ and CD8alpha- DC from either location is greatly increased following their overnight culture in the presence of granulocyte-macrophage colony-stimulating factor. The elevated production of IL-12p70 by short-term cultured DC correlates with their enhanced expression of CD40 and other costimulatory molecules, and elevated T cell-stimulatory capacity. These data indicate that low IL-12-producing capacity is not an intrinsic property of the CDalpha8- DC subtype, and support the hypothesis that factors such as the site of DC development and maturation stage play a dominant role in defining DC function.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12884867     DOI: 10.1002/eji.200323379

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  9 in total

Review 1.  Antigen-presenting cell function in the tolerogenic liver environment.

Authors:  Angus W Thomson; Percy A Knolle
Journal:  Nat Rev Immunol       Date:  2010-11       Impact factor: 53.106

2.  Dendritic cell-T cell interactions: CD8 alpha alpha expressed on dendritic cells regulates T cell proliferation.

Authors:  Li Hong; Tonya J Webb; David S Wilkes
Journal:  Immunol Lett       Date:  2007-01-08       Impact factor: 3.685

3.  Influence of the tissue microenvironment on Toll-like receptor expression by CD11c+ antigen-presenting cells isolated from mucosal tissues.

Authors:  Shunsuke Takenaka; Sarah McCormick; Ekaterina Safroneeva; Zhou Xing; Jack Gauldie
Journal:  Clin Vaccine Immunol       Date:  2009-09-23

Review 4.  Tolerogenic dendritic cells and their applications in transplantation.

Authors:  Haibin Li; Bingyi Shi
Journal:  Cell Mol Immunol       Date:  2014-08-11       Impact factor: 11.530

5.  Dendritic cell populations with different concentrations of lipid regulate tolerance and immunity in mouse and human liver.

Authors:  Junaid Ibrahim; Andrew H Nguyen; Adeel Rehman; Atsuo Ochi; Mohsin Jamal; Christopher S Graffeo; Justin R Henning; Constantinos P Zambirinis; Nina C Fallon; Rocky Barilla; Sana Badar; Aaron Mitchell; Raghavendra S Rao; Devrim Acehan; Alan B Frey; George Miller
Journal:  Gastroenterology       Date:  2012-06-12       Impact factor: 22.682

Review 6.  Dendritic cells: cellular mediators for immunological tolerance.

Authors:  Chun Yuen J Chung; Dirk Ysebaert; Zwi N Berneman; Nathalie Cools
Journal:  Clin Dev Immunol       Date:  2013-05-15

7.  CD11c+ antigen presenting cells from the alveolar space, lung parenchyma and spleen differ in their phenotype and capabilities to activate naïve and antigen-primed T cells.

Authors:  Kapilan Kugathasan; Elizabeth K Roediger; Cherrie-Lee Small; Sarah McCormick; Pingchang Yang; Zhou Xing
Journal:  BMC Immunol       Date:  2008-08-13       Impact factor: 3.615

Review 8.  Various pathways of zoledronic acid against osteoclasts and bone cancer metastasis: a brief review.

Authors:  Lianwei Wang; Dengyang Fang; Jinming Xu; Runlan Luo
Journal:  BMC Cancer       Date:  2020-11-03       Impact factor: 4.430

9.  Phase II Trial of Adjuvant Dendritic Cell Vaccine in Combination with Celecoxib, Interferon-α, and Rintatolimod in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Metastases.

Authors:  Rajesh Ramanathan; Haroon Choudry; Heather Jones; Mark Girgis; William Gooding; Pawel Kalinski; David L Bartlett
Journal:  Ann Surg Oncol       Date:  2021-01-05       Impact factor: 5.344

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.